Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

2.

Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome.

Morici N, Tavecchia GA, Antolini L, Caporale MR, Cantoni S, Bertuccio P, Sacco A, Meani P, Viola G, Brunelli D, Oliva F, Lombardi F, Segreto A, Oreglia JA, La Vecchia C, Cattaneo M, Valgimigli M, Savonitto S.

Angiology. 2019 Oct;70(9):867-877. doi: 10.1177/0003319719848547. Epub 2019 May 14.

PMID:
31088127
3.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamberi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassineti GL, Tassinari D, Giuliani F, Cinieri S, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Parra HS, Fornaro L, Caporale M, de Braud F, Pietrantonio F.

BMC Cancer. 2019 Mar 29;19(1):283. doi: 10.1186/s12885-019-5498-3.

4.

Immunophenotyping of Sheep Paraffin-Embedded Peripheral Lymph Nodes.

Melzi E, Rocchi MS, Entrican G, Caporale M, Palmarini M.

Front Immunol. 2018 Dec 11;9:2892. doi: 10.3389/fimmu.2018.02892. eCollection 2018.

5.

Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.

Berenato R, Morano F, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, de Braud F, Mazzaferro V, Di Bartolomeo M.

Oncology. 2017;93(5):279-286. doi: 10.1159/000479154. Epub 2017 Sep 8.

PMID:
28881354
6.

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, de Braud F, Pezzica E, Di Bartolomeo M, Sgroi G, Mazzaferro V, Pietrantonio F, Barni S.

J Gastrointest Oncol. 2017 Feb;8(1):148-163. doi: 10.21037/jgo.2017.01.10.

7.

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C.

Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810.

8.

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S.

Eur J Cancer. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032. Epub 2016 Dec 18.

9.

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2017 Sep;16(3):e191-e198. doi: 10.1016/j.clcc.2016.09.007. Epub 2016 Oct 6.

PMID:
27979717
10.

Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.

Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M.

Ann Surg Oncol. 2016 Dec;23(13):4222-4230. Epub 2016 Jun 28.

PMID:
27352203
11.

Toward the molecular dissection of peritoneal pseudomyxoma.

Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, de Braud F, Baratti D, Bowne WB, Kusamura S, Deraco M.

Ann Oncol. 2016 Nov;27(11):2097-2103. Epub 2016 Aug 8.

PMID:
27502722
12.

Follicular dendritic cell disruption as a novel mechanism of virus-induced immunosuppression.

Melzi E, Caporale M, Rocchi M, Martín V, Gamino V, di Provvido A, Marruchella G, Entrican G, Sevilla N, Palmarini M.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6238-E6247. Epub 2016 Sep 26.

13.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

14.

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A.

Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5.

15.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F.

Cancer Discov. 2016 Sep;6(9):963-71. doi: 10.1158/2159-8290.CD-16-0297. Epub 2016 Jun 20.

16.

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F.

J Transl Med. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.

17.

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer.

Di Bartolomeo M, Pietrantonio F, Rulli E, Poli D, Berenato R, Caporale M, Bajetta E, Floriani I.

Tumori. 2016 Aug 3;102(4):e15-9. doi: 10.5301/tj.5000480.

PMID:
27032700
18.

Bluetongue Virus NS4 Protein Is an Interferon Antagonist and a Determinant of Virus Virulence.

Ratinier M, Shaw AE, Barry G, Gu Q, Di Gialleonardo L, Janowicz A, Varela M, Randall RE, Caporale M, Palmarini M.

J Virol. 2016 May 12;90(11):5427-39. doi: 10.1128/JVI.00422-16. Print 2016 Jun 1.

19.

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, de Braud F, Di Bartolomeo M, Clementi E, Loupakis F, Pietrantonio F.

Pharmacogenomics J. 2017 Jul;17(4):331-336. doi: 10.1038/tpj.2016.22. Epub 2016 Mar 22.

PMID:
27001121
20.

Mutations in the Schmallenberg Virus Gc Glycoprotein Facilitate Cellular Protein Synthesis Shutoff and Restore Pathogenicity of NSs Deletion Mutants in Mice.

Varela M, Pinto RM, Caporale M, Piras IM, Taggart A, Seehusen F, Hahn K, Janowicz A, de Souza WM, Baumgärtner W, Shi X, Palmarini M.

J Virol. 2016 May 12;90(11):5440-5450. doi: 10.1128/JVI.00424-16. Print 2016 Jun 1.

21.

Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M.

Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12. Review.

PMID:
26907512
22.

BRAF in metastatic colorectal cancer: the future starts now.

Orlandi A, Calegari A, Inno A, Berenato R, Caporale M, Niger M, Bossi I, Di Bartolomeo M, de Braud F, Pietrantonio F.

Pharmacogenomics. 2015 Dec;16(18):2069-81. doi: 10.2217/pgs.15.140. Epub 2015 Nov 30. Review.

PMID:
26615988
23.

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.

Pietrantonio F, de Braud F, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M.

Target Oncol. 2016 Jun;11(3):337-43. doi: 10.1007/s11523-015-0397-2.

PMID:
26538496
24.

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F.

Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7.

25.

Characterization of a second open reading frame in genome segment 10 of bluetongue virus.

Stewart M, Hardy A, Barry G, Pinto RM, Caporale M, Melzi E, Hughes J, Taggart A, Janowicz A, Varela M, Ratinier M, Palmarini M.

J Gen Virol. 2015 Nov;96(11):3280-93. doi: 10.1099/jgv.0.000267. Epub 2015 Aug 19.

26.

Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.

Grassadonia A, Caporale M, Tinari N, Zilli M, DeTursi M, Gamucci T, Vici P, Natoli C.

J Cancer. 2015 May 12;6(6):575-82. doi: 10.7150/jca.11566. eCollection 2015. Review.

27.

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.

Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E, Pietrantonio F.

Int J Mol Sci. 2015 Apr 21;16(4):8884-95. doi: 10.3390/ijms16048884. Review.

28.

Multiple genome segments determine virulence of bluetongue virus serotype 8.

Janowicz A, Caporale M, Shaw A, Gulletta S, Di Gialleonardo L, Ratinier M, Palmarini M.

J Virol. 2015 May;89(10):5238-49. doi: 10.1128/JVI.00395-15. Epub 2015 Mar 11.

29.

Virus and host factors affecting the clinical outcome of bluetongue virus infection.

Caporale M, Di Gialleonorado L, Janowicz A, Wilkie G, Shaw A, Savini G, Van Rijn PA, Mertens P, Di Ventura M, Palmarini M.

J Virol. 2014 Sep;88(18):10399-411. doi: 10.1128/JVI.01641-14. Epub 2014 Jul 2.

30.

NSs protein of Schmallenberg virus counteracts the antiviral response of the cell by inhibiting its transcriptional machinery.

Barry G, Varela M, Ratinier M, Blomström AL, Caporale M, Seehusen F, Hahn K, Schnettler E, Baumgärtner W, Kohl A, Palmarini M.

J Gen Virol. 2014 Aug;95(Pt 8):1640-6. doi: 10.1099/vir.0.065425-0. Epub 2014 May 14.

31.

Non-Hodgkin's lymphoma: unexpected cause of shoulder pain. A systematic review of the literature.

Caporale MF, Gambino GF, Larosa FS, Del Buono A, Di Segni F.

Muscles Ligaments Tendons J. 2013 Aug 11;3(3):236-9. eCollection 2013 Jul.

32.

Transplacental transmission of field and rescued strains of BTV-2 and BTV-8 in experimentally infected sheep.

Rasmussen LD, Savini G, Lorusso A, Bellacicco A, Palmarini M, Caporale M, Rasmussen TB, Belsham GJ, Bøtner A.

Vet Res. 2013 Sep 5;44:75. doi: 10.1186/1297-9716-44-75.

33.

Host species barriers to Jaagsiekte sheep retrovirus replication and carcinogenesis.

Caporale M, Martineau H, De las Heras M, Murgia C, Huang R, Centorame P, Di Francesco G, Di Gialleonardo L, Spencer TE, Griffiths DJ, Palmarini M.

J Virol. 2013 Oct;87(19):10752-62. doi: 10.1128/JVI.01472-13. Epub 2013 Jul 31.

34.

Schmallenberg virus pathogenesis, tropism and interaction with the innate immune system of the host.

Varela M, Schnettler E, Caporale M, Murgia C, Barry G, McFarlane M, McGregor E, Piras IM, Shaw A, Lamm C, Janowicz A, Beer M, Glass M, Herder V, Hahn K, Baumgärtner W, Kohl A, Palmarini M.

PLoS Pathog. 2013 Jan;9(1):e1003133. doi: 10.1371/journal.ppat.1003133. Epub 2013 Jan 10.

35.

Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment.

Shaw AE, Ratinier M, Nunes SF, Nomikou K, Caporale M, Golder M, Allan K, Hamers C, Hudelet P, Zientara S, Breard E, Mertens P, Palmarini M.

J Virol. 2013 Jan;87(1):543-57. doi: 10.1128/JVI.02266-12. Epub 2012 Oct 24.

36.

Identification and characterization of a novel non-structural protein of bluetongue virus.

Ratinier M, Caporale M, Golder M, Franzoni G, Allan K, Nunes SF, Armezzani A, Bayoumy A, Rixon F, Shaw A, Palmarini M.

PLoS Pathog. 2011 Dec;7(12):e1002477. doi: 10.1371/journal.ppat.1002477. Epub 2011 Dec 29.

37.

Determinants of bluetongue virus virulence in murine models of disease.

Caporale M, Wash R, Pini A, Savini G, Franchi P, Golder M, Patterson-Kane J, Mertens P, Di Gialleonardo L, Armillotta G, Lelli R, Kellam P, Palmarini M.

J Virol. 2011 Nov;85(21):11479-89. doi: 10.1128/JVI.05226-11. Epub 2011 Aug 24.

38.

The signal peptide of a recently integrated endogenous sheep betaretrovirus envelope plays a major role in eluding gag-mediated late restriction.

Armezzani A, Arnaud F, Caporale M, di Meo G, Iannuzzi L, Murgia C, Palmarini M.

J Virol. 2011 Jul;85(14):7118-28. doi: 10.1128/JVI.00407-11. Epub 2011 May 18.

39.

Lung adenocarcinoma originates from retrovirus infection of proliferating type 2 pneumocytes during pulmonary post-natal development or tissue repair.

Murgia C, Caporale M, Ceesay O, Di Francesco G, Ferri N, Varasano V, de las Heras M, Palmarini M.

PLoS Pathog. 2011 Mar;7(3):e1002014. doi: 10.1371/journal.ppat.1002014. Epub 2011 Mar 31.

40.

The signal peptide of a simple retrovirus envelope functions as a posttranscriptional regulator of viral gene expression.

Caporale M, Arnaud F, Mura M, Golder M, Murgia C, Palmarini M.

J Virol. 2009 May;83(9):4591-604. doi: 10.1128/JVI.01833-08. Epub 2009 Feb 25.

41.

Colostrum and milk can transmit jaagsiekte retrovirus to lambs.

Grego E, De Meneghi D, Alvarez V, Benito AA, Minguijón E, Ortín A, Mattoni M, Moreno B, Pérez de Villarreal M, Alberti A, Capucchio MT, Caporale M, Juste R, Rosati S, De las Heras M.

Vet Microbiol. 2008 Aug 25;130(3-4):247-57. doi: 10.1016/j.vetmic.2008.01.011. Epub 2008 Feb 7.

PMID:
18328646
42.

A paradigm for virus-host coevolution: sequential counter-adaptations between endogenous and exogenous retroviruses.

Arnaud F, Caporale M, Varela M, Biek R, Chessa B, Alberti A, Golder M, Mura M, Zhang YP, Yu L, Pereira F, Demartini JC, Leymaster K, Spencer TE, Palmarini M.

PLoS Pathog. 2007 Nov;3(11):e170.

43.

Miller Fisher syndrome and Escherichia coli infection: is it a novel association?

Blasetti A, Cerruto M, Cutarella R, Tocco A, Caporale MC, Chiarelli F, Verrotti A.

J Child Neurol. 2007 Jan;22(1):71-3.

PMID:
17608309
44.

Expression of the jaagsiekte sheep retrovirus envelope glycoprotein is sufficient to induce lung tumors in sheep.

Caporale M, Cousens C, Centorame P, Pinoni C, De las Heras M, Palmarini M.

J Virol. 2006 Aug;80(16):8030-7.

45.

[Human science and medicine].

Caporale M.

Med Secoli. 2005;17(1):243-9. Italian.

PMID:
16285093
46.

Infection of lung epithelial cells and induction of pulmonary adenocarcinoma is not the most common outcome of naturally occurring JSRV infection during the commercial lifespan of sheep.

Caporale M, Centorame P, Giovannini A, Sacchini F, Di Ventura M, De las Heras M, Palmarini M.

Virology. 2005 Jul 20;338(1):144-53.

47.

Late viral interference induced by transdominant Gag of an endogenous retrovirus.

Mura M, Murcia P, Caporale M, Spencer TE, Nagashima K, Rein A, Palmarini M.

Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11117-22. Epub 2004 Jul 19.

48.

An improved methodology for the synthesis of enantiomerically pure (S)-2,3-O-cyclohexylideneglyceraldehyde.

Benaglia M, Caporale M, Puglisi A.

Enantiomer. 2002 Nov-Dec;7(6):383-5.

PMID:
12643315
49.

Cocaine use and the mid-latency auditory evoked responses.

Boutros N, Campbell D, Petrakis I, Krystal J, Caporale M, Kosten T.

Psychiatry Res. 2000 Oct 30;96(2):117-26.

PMID:
11063784
50.

Analysis of a failed alumina THR ball head.

Piconi C, Labanti M, Magnani G, Caporale M, Maccauro G, Magliocchetti G.

Biomaterials. 1999 Sep;20(18):1637-46. Review.

PMID:
10503966

Supplemental Content

Loading ...
Support Center